Check-Cap Ltd. (CHEK) Research

Check-Cap Ltd. is an Israeli medical diagnostics company currently in the clinical development phase. It is dedicated to advancing a novel capsule-based screening method that employs ultra-low-dose X-rays. This technology is designed to thoroughly examine the internal surface of the colon, aiming to identify precancerous polyps and other structural irregularities. The company's primary offering, the C-Scan system, is composed of three integral parts: the C-Scan Cap, an ingestible X-ray scanning capsule for detecting suspected polyps; the C-Scan Track, a disposable unit that adheres to the patient's back via biocompatible adhesive patches; and the C-Scan View software. This client/server application enables the download of procedural data from the C-Scan Track, performs detailed analysis, and generates comprehensive reports. Check-Cap Ltd. was founded in 2004 and operates from its headquarters in Isfiya, Israel.

Market snapshot

Symbol
CHEK
Price
$1.86
Day change
+1.64%
Market cap
$8.4M
P/E ratio
2.17x
52-week range
0.56-3.13
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Adial Pharmaceuticals, Inc. (ADIL)
  • Biofrontera Inc. (BFRI)
  • GBS Inc. (GBS)
  • HCW Biologics Inc. (HCWB)
  • Innovative Eyewear, Inc. (LUCY)
  • Mainz Biomed B.V. (MYNZ)
  • NeuroSense Therapeutics Ltd. (NRSN)

Open Check-Cap Ltd. (CHEK) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.